WallStreetZenWallStreetZen

NASDAQ: GDTC
Cytomed Therapeutics Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their GDTC stock forecasts and price targets.

Forecast return on equity

Is GDTC forecast to generate an efficient return?

Company
-35.84%
Industry
-29.7%
Market
371.4%
GDTC's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is GDTC forecast to generate an efficient return on assets?

Company
-30.65%
Industry
7.87%
GDTC is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

GDTC earnings per share forecast

What is GDTC's earnings per share in the next 1 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$0.17

GDTC revenue forecast

What is GDTC's revenue in the next 1 years based on estimates from 3 analysts?

Avg 1 year Forecast
$530.4k+201.22%

GDTC vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
GDTC$1.74N/AN/A
MRKR$1.19N/AN/A
NNVC$1.09N/AN/A
CASI$0.93$4.00+329.18%Buy
ALLR$1.20$9.25+670.83%Buy
View Top Biotech Stocks

Cytomed Therapeutics Stock Forecast FAQ

What is GDTC's earnings growth forecast for 2025-2025?

(NASDAQ: GDTC) Cytomed Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of N/A, and while it is not forecast to beat the US market's average forecast earnings growth rate of N/A.

Cytomed Therapeutics's earnings in 2025 is -$2,868,796.

In 2025, GDTC is forecast to generate -$2,001,036 in earnings, with the lowest earnings forecast at -$1,922,564 and the highest earnings forecast at -$2,059,890.

If you're new to stock investing, here's how to buy Cytomed Therapeutics stock.

What is GDTC's revenue growth forecast for 2025-2025?

(NASDAQ: GDTC) Cytomed Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of N/A, and while it is not forecast to beat the US market's average forecast revenue growth rate of N/A.

Cytomed Therapeutics's revenue in 2025 is $176,084.

In 2025, GDTC is forecast to generate $6,120,816 in revenue, with the lowest revenue forecast at $5,880,784 and the highest revenue forecast at $6,300,840.

What is GDTC's forecast return on assets (ROA) for 2025-2025?

(NASDAQ: GDTC) forecast ROA is -30.65%, which is lower than the forecast US Biotechnology industry average of 7.87%.

What is GDTC's Earnings Per Share (EPS) forecast for 2025-2025?

(NASDAQ: GDTC) Cytomed Therapeutics's current Earnings Per Share (EPS) is -$0.25. In 2025, GDTC's EPS is forecast to hit -$0.17 (min: -$0.17, max: -$0.18).

What is GDTC's forecast return on equity (ROE) for 2025-2025?

(NASDAQ: GDTC) forecast ROE is -35.84%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.